Dienstag, 15. Juni 2021
Navigation öffnen
JOURNAL ONKOLOGIE – STUDIE
BAZE

Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

Noch nicht rekrutierend

NCT-Nummer:
NCT04812808

Studienbeginn:
Mai 2021

Letztes Update:
24.03.2021

Wirkstoff:
Bazedoxifene 20 mg

Indikation (Clinical Trials):
Adenocarcinoma, Pancreatic Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Vignot Lucie

Collaborator:
-

Studienlocations
(1 von 1)

Studien-Informationen

Detailed Description:

This study is a single-center, prospective, non-randomized trial. The population studied will

consist of 10 patients of both sexes, aged 18 to 85 years, with a newly diagnosed metastatic

pancreatic adenocarcinoma who will undergo palliative treatment with standard first line

chemotherapy (Gemcitabine +/- Nab-paclitaxel). Diagnosis must be confirmed by biopsy and

metastasis must be accessible for percutaneous biopsy using imaging guidance.

In addition to chemotherapy, patients will receive 20 mg bazedoxifene (Conbriza®) orally per

day, subject to good clinical tolerance and in the absence of a biological contraindication.

Patients will receive bazedoxifene once a day at any time, with or without meals. Initiation

of treatment will be simultaneous to the initiation of chemotherapy. Bazedoxifene (Conbriza®)

will be prescribed and administered for the duration of the study. To minimize the risk of

thrombo-embolic events, prophylactic acetyl-salicylic acid (Aspirin®) 100 mg orally once per

day will be added for the duration of the bazedoxifene (Conbriza®) intake. Pantoprazole 20 mg

once per day will be added in selected patients to minimize gastric complications according

to the physician's appreciation. Participants will receive bazedoxifene (Conbriza®) and

acetylsalicylic acid (Aspirin®) for the entire study duration from a subinvestigator at

treatment initiation visit.

Physical examination with vital parameters, laboratory testing (blood count, liver enzymes,

creatinine) and tumor marker (CA 19-9) will be conducted in order to determine the baseline

prior to the initiation of the treatment. The quality of life using the EORTC core quality of

life questionnaire (QLQ-C30) will also be assessed at that point. Furthermore, the IL-6

pathway activity (GP130/STAT3) will be assessed immunohistochemically on metastasis biopsy

before administration of bazedoxifene (Conbriza®). The tissue will be obtained by

percutaneous biopsy using imaging guidance. A biopsy performed before study inclusion can be

used as baseline to avoid a second biopsy.

Study enrollment and follow-up will be performed by the consultant physician at the HFR

Fribourg in the department of oncology. The follow-up will be carried out every 3 to 4 weeks

and will consist of a physical examination, vital parameters, laboratory testing (blood

count, liver enzymes, creatinine, electrolytes) and tumor marker (CA 19-9). Plasma samples

will be collected before and after treatment for storage and samples will be analyzed through

next generation sequencing NGS. Quality-of-life will be assessed during the follow-ups and

drug adherence will be monitored through patient survey.

After 3 months of treatment, the primary endpoint will be assessed. Thoraco-abdominal CT scan

or PET-CT will be performed, and a biopsy of metastasis tissue will be repeated (percutaneous

under radiological guidance) for immunohistochemical IL-6 pathway activity (GP130/STAT3)

analysis. The pathologist as primary endpoint assessor will be blinded. The activity of

bazedoxifene (Conbriza®) on inflammatory pathways and tumor progression will be evaluated by

comparing the modification in expression of the IL-6 pathway (GP130/STAT3) from baseline.

Patients will be instructed by the investigator to report the occurrence of any adverse

event. Security outcomes will also be compared between the intervention and the control

group.

The expected duration of participants participation will be 3 months.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Adults aged from 18 to 85,

- Newly diagnosed metastatic pancreatic adenocarcinoma (stage IV according to AJCC)

- Accessible metastasis for percutaneous biopsy using imaging guidance

- Palliative chemotherapy planned,

- Informed Consent as documented by signature (Appendix Informed Consent Form).

Exclusion Criteria:

- No treatment for pancreatic adenocarcinoma,

- Curative treatment of pancreatic adenocarcinoma,

- No accessible metastasis for biopsy,

- Previous thrombo-embolic events,

- Known hypersensibility or allergy to bazedoxifene or one of the Conbriza excipient,

- Women who are pregnant or breast feeding,

- Intention to become pregnant during the course of the study,

- Lack of safe contraception, defined as: Female participants of childbearing potential,

not using and not willing to continue using a medically reliable method of

contraception for the entire study duration, such as oral, injectable, or implantable

contraceptives, or intrauterine contraceptive devices, or who are not using any other

method considered sufficiently reliable by the investigator in individual cases.

Female participants who are surgically sterilised / hysterectomised or post-menopausal

for longer than 2 years are not considered as being of childbearing potential.

- Other clinically significant concomitant disease states (e.g., renal failure, hepatic

dysfunction, cardiovascular disease, etc.),

- Known or suspected non-compliance, drug or alcohol abuse,

- Inability to follow the procedures of the study, e.g. due to language problems,

psychological disorders, dementia, etc. of the participant,

- Inability to give informed consent,

- Participation in another study with investigational drug within the 30 days preceding

and during the present study,

- Previous enrolment into the current study,

- Enrolment of the investigator, his/her family members, employees and other dependent

persons

Studien-Rationale

Primary outcome:

1. IL-6/GP-130/STAT3 pathway modification (%) (Time Frame - 3 months):
IL-6 (GP130/STAT3) by immunohistochemistry on metastasis biopsy before and after treatment with bazedoxifene in addition to chemotherapy.



Secondary outcome:

1. Carbohydrate-Antigen 19-9 (CA 19-9) in U/ml (Time Frame - every 3 weeks for 3 months):
The change in tumor marker CA 19-9 as a reflection of tumor progression. CA 19-9 will be measured on blood samples collected every 3 to 4 weeks throughout the trial and compared with the baseline prior to treatment initiation.

2. EORTC core quality of life questionnaire (QLQ-C30) (Time Frame - every 3 weeks for 3 months):
Quality of life using the quality-of-life questionnaire EORTC QLQ-C30. This variable will be measured every 3 to 4 weeks throughout the trial and compared with the baseline prior to treatment initiation. Score ranging from 0 to 100. High scale score represents a higher response level.

3. Heart rate (bpm) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

4. Blood pressure (mmHg) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

5. Oxygen saturation (%) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

6. weight (kg) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

7. body temperature (°Celcius) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

8. liver enzymes (GOT/ASAT in U/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

9. liver enzymes (GPT/ALAT in U/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

10. liver enzymes (GGT in U/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

11. liver enzymes (alkaline phosphatase in U/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

12. liver enzymes (bilirubine in umol/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

13. renal parameters (creatinine in umol/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

14. electrolytes (sodium in mmol/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

15. electrolytes (potassium in mmol/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

16. electrolytes (phosphate in mmol/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

17. electrolytes (calcium in mmol/l) (Time Frame - every 3 weeks for 3 months):
Assess toxicity of bazedoxifene in combination with chemotherapy. Physical examination will be performed and blood samples, including renal and hepatic parameters, will be analyzed every 3 to 4 weeks.

Geprüfte Regime

  • Bazedoxifene 20 mg:
    Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy. Prophylactic acetyl-salicylic acid (Aspirin®) 100 mg per day orally will be added to avoid thromboembolic events.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose
  • Hochrisiko-MDS und AML: Sabatolimab + Decitabin/Azacitidin zeigt in Phase-I-Studie anhaltende Remissionen bei guter Verträglichkeit
  • PNH: Neuer oraler Faktor-B-Inhibitor Iptacopan zeigt in Phase-II-Studie Wirksamkeit in der Erstlinie